All In Biotech

Drug Trial Radar · NCT00553293

Nordic Luveris Study

Recombinant LH Supplementation to Recombinant FSH During the Final Days of Controlled Ovarian Stimulation for IVF: a Multicentre, Prospective, Randomized, Controlled Trial

Last checked: Nov 20, 2026Latest source record: Nov 5, 2007 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 526 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

526

Actual

Start

Aug 2003

Primary completion

Not stated

Study completion Nov 2004

Sponsor

Lead sponsor
Copenhagen University Hospital, RigshospitaletAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Regionshospitalet Viborg, Skive; Karolinska University Hospital; Helse Fonna; Turku Hospital; Odense University Hospital; Herlev Hospital; Holbaek Sygehus; Hvidovre University Hospital
First posted
Nov 5, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
Female only, from 21 years, up to 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To study whether addition of human LH hormone (Luveris) during the final days of stimulation with recombinant FSH (Gonal-f) for controlled ovarian stimulation will be of benefit for patients undergoing in vitro fertilisation.

Conditions

  • Infertility
  • In Vitro Fertilization

Interventions

  • recombinant luteinizing hormone (Luveris)Drug

    75 iu/day form cycle day 6

  • recombinant follicle stimulating hormone (Gonal-f)Drug

    rFSH 150 iu/day

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Ongoing pregnancy rate per started stimulation cycleTime frame: ultrasound showing ongoing pregnancy

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Anders Nyboe Andersen

    Copenhagen, Copenhagen, Denmark

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.